Pharmafile Logo
Pharmafocus logo
Advanced Search

keytruda

Showing 15 posts of 134 posts found.

merckentranceweb

Keytruda continues success with new Phase 3 data in adjuvant melanoma

April 16, 2018
Research and Development, Sales and Marketing Cancer, MSD, keytruda, melanoma, pharma, skinc cancer

MSD has revealed new efficacy data for Keytruda (permbrolizumab) as an adjuvant therapy in the treatment of resected, high-risk stage …

News
msd

Keytruda scores big as a first-line monotherapy in NSCLC patients with any level of PD-L1 expression

April 10, 2018
Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

Closely following the news that Keytruda (pembrolizumab) had failed in the treatment of unresectable or metastatic melanoma as a combination …

News
merckincweb

Keytruda combo fails at Phase 3 in metastatic melanoma

April 9, 2018
Research and Development, Sales and Marketing Incyte, MSD, keytruda, pharma, trial failure

Shares in biopharma firm Incyte were sent reeling by as much as 20% when the company announced that the results …

News

NICE recommends Keytruda via CDF as first and only urothelial carcinoma immunotherapy

March 16, 2018
Medical Communications, Sales and Marketing MSD, NICE, immunotherapy, keytruda, pharma

UK drugs watchdog NICE has published its finance guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS through …

News
shutterstock_273326141

Eisai and MSD team up to combine Lenvima and Keytruda in cancer

March 8, 2018
Sales and Marketing Cancer, Eisai, Kidney cancer, Lenvima, MSD, Merck, keytruda, pharma

Pharma heavyweights MSD (Merck) and Eisai have announced they are to join forces to develop and commercialise the latter’s tyrosine …

News
japan-112722_640

Japan saves record $12.2bn in 2017 through greater generic use

March 7, 2018
Research and Development, Sales and Marketing Japan, generics, keytruda, opdivo, pharma

Through a concerted shift from branded drugs to generic equivalents as a means to lower prescription costs, Japan is estimated …

News
merckincweb

MSD poised to acquire viral immuno-oncology firm Viralytics for $394m

February 21, 2018
Research and Development, Sales and Marketing Cancer, MSD, Merck, Viralytics, acquisition, keytruda, oncology, pharma

MSD, known as Merck in the US, has announced it is to buy Australian viral immuno-oncology firm Viralytics for $394 …

News
merckwindowweb

MSD’s interim Keytruda combo data spooks Roche and BMS

January 16, 2018
Research and Development MSD, Merck, biotech, drugs, keytruda, pharma, pharmaceutical

When PD-1/L1 treatments first came on the market, there was a race to snaffle as many indications as possible for …

News
merckwindowweb

Keytruda falls hard at gastric cancer hurdle

December 18, 2017
Research and Development, Sales and Marketing MSD, biotech, drugs, keytruda, pharma, pharmaceutical

There was a time when PD-1/L1 immunotherapy treatments could do no wrong, blasting through indication after indication. However, the limits …

News

MSD withdraws European application of Keytruda combo in lung cancer

October 30, 2017
Sales and Marketing EMA, MSD, keytruda

MSD has been forced to withdraw its EU marketing application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as …

News
merckwindowweb

MSD plays catch up with €464m deal for fledgling biotech

September 7, 2017
Sales and Marketing Bristol-Myers Squibb, MSD, biotech, drugs, keytruda, pharma, pharmaceutical

MSD has announced that it will acquire Rigontec, a three-year old German biotech, in a deal worth an initial €115 …

News
merck_and_co

MSD’s Keytruda hits rare snag, floundering in confirmatory trial

July 25, 2017
Manufacturing and Production, Sales and Marketing MSD, Merck, biotech, drugs, keytruda, pharma, pharmaceutical

Since the PD-1/PD-L1 immunotherapies have hit the market, they have revolutionised cancer care for many patients yet, with the science …

News
merck_entrance

FDA shutters MSD’s Keytruda combination trials in myeloma

July 6, 2017
Medical Communications, Research and Development MSD, immunotherapy, keytruda, pd-1

Following on from the news last month that enrolment for Keytruda being used alongside Celgene’s Imnovid and Revlimid would have …

News
microscope-275984_960_720

LifeArc rebrands and sets up £500m research fund

June 15, 2017
Medical Communications, Research and Development, Sales and Marketing LifeArc, MRC Technology, keytruda

The UK medical research charity formerly known as MRC Technology has rebranded to be known as LifeArc. At the same …

News
keytruda3-web

MSD receives first FDA approval based on specific genetic feature

May 24, 2017
Research and Development, Sales and Marketing MSD, Precision Medicine, biomarker, keytruda

In a historic first, MSD (known as Merck in North America) has received approval for its immunotherapy treatment Keytruda in …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025